Regeneron Pharmaceuticals (REGN) Collaboration summary

Opening remarks and agenda

• Expanded global alliance opens a new chapter in a 20-year collaboration focused on next-generation Type 2 medicines.

• Prepared remarks covered partnership strategy, pipeline, deal terms and operations, followed by Q&A.

Objectives of the partnership

• Extend the alliance beyond DUPIXENT and sustain leadership in Type 2 inflammatory diseases with differentiated, long-acting treatments.

• Pursue longer dosing intervals without compromising efficacy or safety, addressing treatment burden and patient convenience.

• Combine antibody discovery and development expertise with global development and commercial capabilities to accelerate access worldwide.

Partner introductions and roles

• Four fully human, long-acting antibodies join the alliance: IL-13, IL-4/IL-13 bispecific, IL-4 receptor alpha and IL-4 antibodies.

• Sanofi provides an option to add lunsekimig, an IL-13/TSLP Nanobody, at the alliance's discretion following COPD Phase III results.

• Regeneron leads development decisions; Sanofi retains final commercial decisions, including access and pricing, with increased payer-engagement participation for Regeneron.

• Sanofi's global development, commercial, supply, device and patient-support capabilities complement antibody discovery and joint immunology expertise.